PharmaJet presents latest research showing Benefits of Needle-free at Military Health System Research Symposium

Needle-free systems provide significant protection against disease and viremia

GOLDEN, Colo. — September 12, 2022 — PharmaJet®, a company who has developed and commercialized a needle-free platform to more effectively administer drugs and biologics, today announced that they will present their latest research results at the Military Health System Research Symposium (MHSRS) on September 13, 2022. The presentation, entitled Advancement of a Next Generation Needle-Free Injection Device for Effective Delivery of the Venezuelan Equine Encephalitis Virus DNA Vaccine, will be presented by Erin Spiegel, Ph.D., Vice President of Clinical and Regulatory Affairs at PharmaJet. The MHSRS is the foremost scientific meeting for the Department of Defense providing a venue for presenting new scientific knowledge resulting from military-unique research and development.

The published study1 was part of the previously announced multi-year, multi-million dollar award from the Joint Science and Technology Office of the U.S. Defense Threat Reduction Agency (DTRA) funding the use of needle-free technology to further progress promising nucleic acid vaccines, and the development of PharmaJet’s next generation needle-free devices. Delivery of the Venezuelan equine encephalitis DNA vaccine with the PharmaJet Stratis® (Intramuscular – IM) or PharmaJet Tropis® (Intradermal – ID) Needle-free Injection Systems (NFIS) resulted in humoral and cellular immune responses that provided significant protection against disease and viremia. Although the ID route utilized one-fifth of the DNA dose, the level of protection was high and outperformed the IM route for several clinical endpoints including fever and viremia. Additionally, the PharmaJet NFIS overcame the drawbacks of electroporation, being easier to use and not requiring a power source.

“We are excited about the continued success of our collaboration with our U.S. Government to advance their vaccine development program and are encouraged by the results of this study. Our partners have published multiple studies showing higher immunogenicity of DNA vaccines delivered with our NFIS. In addition, the PharmaJet Systems are easy-to-use and optimized for military field use,” said Chris Cappello, President and Chief Executive Officer, PharmaJet, Inc.

For more information about PharmaJet visit www.pharmajet.com.

Refer to Instructions for Use to ensure safe injections and to review risks.

1 Suschak, J. et al, A DNA vaccine targeting VEE virus delivered by needle-free jet-injection protects macaques against aerosol challenge, npj Vaccines (22 April 2022)7:46; https://doi.org/10.1038/s41541-022-00469-x

About PharmaJet
PharmaJet’s mission is to enable greater access to life improving pharmaceuticals. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet’s Needle-free Injection Systems provide increased vaccine effectiveness, a preferred patient and caregiver experience, and a proven path to market. They are also safe, fast, and easy-to-use. The Stratis® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis® System has CE Mark and WHO PQS certification for intradermal injections. For more information visit www.pharmajet.com. Follow us on LinkedIn.

About the Military Health System Research Symposium (MHSRS)
The MHSRS is the Department of Defense’s foremost scientific meeting held annually drawing approximately 3,500 attendees. This four-day educational symposium provides a venue for presenting new scientific knowledge resulting from military-unique research and development. Additionally, it provides a collaborative setting for the exchange of information between military providers with deployment experience, research and academic scientists, international partners, and industry on research and related health care initiatives falling under the topic areas of Combat Casualty Care, Military Operational Medicine, Clinical and Rehabilitative Medicine, Medical Simulation and Information Sciences, Military Infectious Diseases, and the Radiation Health Effects.

Menu